{"topic":{"slug":"cardiovascular-innovation","name":"Cardiovascular Therapeutics","domain":"medicine","description":"Lipoprotein(a)-lowering drugs, siRNA and gene-editing approaches to LDL cholesterol, CETP inhibition and other cardiovascular advances.","keywords":["cardiovascular"],"paper_count":252,"latest_published":"2026-10-12","url":"https://space-kitty.com/topics/cardiovascular-innovation","api_url":"https://space-kitty.com/api/v1/topics/cardiovascular-innovation"},"dossier":null,"top_papers":[{"id":"doi:10.1056/nejmoa1615664","kind":"article","title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","authors":["Marc Steven Sabatine","Robert Patrick Giugliano","ANTHONY C. KEECH","Narimon Honarpour","Stephen D. Wiviott","Sabina A. Murphy"],"author_count":12,"year":2017,"published":"2017-03-17","venue":"New England Journal of Medicine","cited_by":6134,"doi":"10.1056/nejmoa1615664","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1056/nejmoa1615664","archive_url":"https://space-kitty.com/papers/doi:10.1056/nejmoa1615664"},{"id":"doi:10.1093/eurheartj/ehx144","kind":"article","title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","authors":["Brian A. Ference","Henry N. Ginsberg","Ian M Graham","Kausik Kumar Ray","Chris J. Packard","Éric Bruckert"],"author_count":26,"year":2017,"published":"2017-03-08","venue":"European Heart Journal","cited_by":3961,"doi":"10.1093/eurheartj/ehx144","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1093/eurheartj/ehx144","archive_url":"https://space-kitty.com/papers/doi:10.1093/eurheartj/ehx144"},{"id":"doi:10.1056/nejmoa1801174","kind":"article","title":"Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome","authors":["Gregory G. Schwartz","Philippe Gabríel Steg","Michael J. Szarek","Deepak L. Bhatt","Vera Bittner","Rafael Díaz"],"author_count":22,"year":2018,"published":"2018-11-07","venue":"New England Journal of Medicine","cited_by":3628,"doi":"10.1056/nejmoa1801174","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1056/nejmoa1801174","archive_url":"https://space-kitty.com/papers/doi:10.1056/nejmoa1801174"},{"id":"doi:10.1056/nejmoa1812792","kind":"article","title":"Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia","authors":["Deepak L. Bhatt","Philippe Gabríel Steg","Michael J. Miller","Eliot A. Brinton","Terry A. Jacobson","Steven B. Ketchum"],"author_count":12,"year":2018,"published":"2018-11-10","venue":"New England Journal of Medicine","cited_by":3316,"doi":"10.1056/nejmoa1812792","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1056/nejmoa1812792","archive_url":"https://space-kitty.com/papers/doi:10.1056/nejmoa1812792"},{"id":"doi:10.1056/nejmoa1501031","kind":"article","title":"Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events","authors":["Jennifer G. Robinson","Michel Farnier","Michel Krempf","Jean Bergeron","Gérald Luc","Maurizio Rocco Averna"],"author_count":16,"year":2015,"published":"2015-03-15","venue":"New England Journal of Medicine","cited_by":2295,"doi":"10.1056/nejmoa1501031","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1056/nejmoa1501031","archive_url":"https://space-kitty.com/papers/doi:10.1056/nejmoa1501031"},{"id":"doi:10.1093/eurheartj/ehac361","kind":"article","title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","authors":["Florian Kronenberg","Samia Mora","Erik S.G. Stroes","Brian A. Ference","Benoît J. Arsenault","Lars Berglund"],"author_count":22,"year":2022,"published":"2022-08-18","venue":"European Heart Journal","cited_by":1448,"doi":"10.1093/eurheartj/ehac361","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1093/eurheartj/ehac361","archive_url":"https://space-kitty.com/papers/doi:10.1093/eurheartj/ehac361"},{"id":"doi:10.1001/jama.2016.13985","kind":"review","title":"Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions","authors":["Michael G. Silverman","Brian A. Ference","Kyungah Im","Stephen D. Wiviott","Robert Patrick Giugliano","Scott M. Grundy"],"author_count":8,"year":2016,"published":"2016-09-27","venue":"JAMA","cited_by":1482,"doi":"10.1001/jama.2016.13985","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1001/jama.2016.13985","archive_url":"https://space-kitty.com/papers/doi:10.1001/jama.2016.13985"},{"id":"doi:10.1016/s2213-8587(22)00353-9","kind":"article","title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial","authors":["Ray KK","Troquay RPT","Visseren FLJ","Leiter LA","Scott Wright R","Vikarunnessa S"],"author_count":11,"year":2023,"published":"2023-01-05","venue":"The lancet. Diabetes & endocrinology","cited_by":257,"doi":"10.1016/s2213-8587(22)00353-9","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1016/s2213-8587(22)00353-9","archive_url":"https://space-kitty.com/papers/doi:10.1016/s2213-8587(22)00353-9"},{"id":"doi:10.1093/eurheartj/ehr112","kind":"review","title":"Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management","authors":["M. John Chapman","Henry N. Ginsberg","Pierre Amarenco","Felicita Andreotti","Jan Borén","Alberico Luigi Catapano"],"author_count":20,"year":2011,"published":"2011-04-29","venue":"European Heart Journal","cited_by":1227,"doi":"10.1093/eurheartj/ehr112","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1093/eurheartj/ehr112","archive_url":"https://space-kitty.com/papers/doi:10.1093/eurheartj/ehr112"},{"id":"doi:10.1038/s41392-023-01690-3","kind":"review","title":"Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside","authors":["Bao X","Liang Y","Chang H","Cai T","Feng B","Gordon K"],"author_count":10,"year":2024,"published":"2024-01-08","venue":"Signal transduction and targeted therapy","cited_by":145,"doi":"10.1038/s41392-023-01690-3","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1038/s41392-023-01690-3","archive_url":"https://space-kitty.com/papers/doi:10.1038/s41392-023-01690-3"},{"id":"doi:10.1016/j.jacc.2016.11.042","kind":"review","title":"A Test in Context: Lipoprotein(a)","authors":["Sotirios Tsimikas"],"author_count":1,"year":2017,"published":"2017-02-01","venue":"Journal of the American College of Cardiology","cited_by":1136,"doi":"10.1016/j.jacc.2016.11.042","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1016/j.jacc.2016.11.042","archive_url":"https://space-kitty.com/papers/doi:10.1016/j.jacc.2016.11.042"},{"id":"doi:10.1056/nejmoa1905239","kind":"article","title":"Lipoprotein(a) Reduction in Persons with Cardiovascular Disease","authors":["Sotirios Tsimikas","Ewa Karwatowska‐Prokopczuk","Ioanna Gouni‐Berthold","Jean‐Claude Tardif","Seth J. Baum","Elizabeth Steinhagen-Thiessen"],"author_count":15,"year":2020,"published":"2020-01-01","venue":"New England Journal of Medicine","cited_by":1090,"doi":"10.1056/nejmoa1905239","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1056/nejmoa1905239","archive_url":"https://space-kitty.com/papers/doi:10.1056/nejmoa1905239"},{"id":"doi:10.1093/eurheartj/ehab551","kind":"article","title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society","authors":["Henry N. Ginsberg","Chris J. Packard","M. John Chapman","Jan Borén","Carlos Alberto Aguilar-Salinas","Maurizio Rocco Averna"],"author_count":22,"year":2021,"published":"2021-07-30","venue":"European Heart Journal","cited_by":978,"doi":"10.1093/eurheartj/ehab551","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1093/eurheartj/ehab551","archive_url":"https://space-kitty.com/papers/doi:10.1093/eurheartj/ehab551"},{"id":"doi:10.4158/ep171764.appgl","kind":"article","title":"American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease","authors":["Paul S. Jellinger","Yehuda Handelsman","Paul D. Rosenblit","Zachary T. Bloomgarden","Vivian Andrew Fonseca","Alan J. Garber"],"author_count":48,"year":2017,"published":"2017-04-01","venue":"Endocrine Practice","cited_by":1093,"doi":"10.4158/ep171764.appgl","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.4158/ep171764.appgl","archive_url":"https://space-kitty.com/papers/doi:10.4158/ep171764.appgl"},{"id":"doi:10.1016/j.cjca.2021.03.016","kind":"article","title":"2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults","authors":["Glen J. Pearson","George Thanassoulis","Todd J. Anderson","Arden R. Barry","Patrick Couture","Natalie Dayan"],"author_count":26,"year":2021,"published":"2021-03-27","venue":"Canadian Journal of Cardiology","cited_by":848,"doi":"10.1016/j.cjca.2021.03.016","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1016/j.cjca.2021.03.016","archive_url":"https://space-kitty.com/papers/doi:10.1016/j.cjca.2021.03.016"}],"newest_papers":[{"id":"doi:10.1016/j.ejphar.2026.179420","kind":"review","title":"Effectiveness and safety of target-specific RNA-based lipid-lowering therapies: A systematic review and meta-analysis of randomized controlled trials","authors":["Widjaja JS","Adji AS","Baraja A","Dharmasaputra A","Rosyadi RN","Komalasari I"],"author_count":10,"year":2026,"published":"2026-10-12","venue":"European journal of pharmacology","cited_by":0,"doi":"10.1016/j.ejphar.2026.179420","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1016/j.ejphar.2026.179420","archive_url":"https://space-kitty.com/papers/doi:10.1016/j.ejphar.2026.179420"},{"id":"doi:10.1016/j.atherosclerosis.2026.121912","kind":"article","title":"Lipoprotein(a) reduction with PCSK9-targeting pharmacotherapy: A prospective real-world registry study","authors":["Kafol J","Fras Z","Novakovic M","Cevc M","Krevel B","Kafol L"],"author_count":12,"year":2026,"published":"2026-09-23","venue":"Atherosclerosis","cited_by":0,"doi":"10.1016/j.atherosclerosis.2026.121912","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1016/j.atherosclerosis.2026.121912","archive_url":"https://space-kitty.com/papers/doi:10.1016/j.atherosclerosis.2026.121912"},{"id":"arxiv:2609.25964","kind":"preprint","title":"Simulation and Analysis of Solute Transport in Multi-Lymphangion Lymphatic Vessels","authors":["Timo Jakumeit","Thiha Aung","Robert Schober","Maximilian Schäfer"],"author_count":4,"year":2026,"published":"2026-09-22","venue":null,"cited_by":0,"doi":null,"arxiv_id":"2609.25964","nct_id":null,"source_url":"https://arxiv.org/abs/2609.25964","archive_url":"https://space-kitty.com/papers/arxiv:2609.25964"},{"id":"doi:10.3390/diagnostics16183009","kind":"article","title":"Serial Coronary Plaque Composition After Inclisiran Initiation Assessed by Automated CCTA: A Retrospective Pilot Study","authors":["Kawada K","Suzuki M","Mochizuki J","Matsumi H","Miura D","Hata Y"],"author_count":6,"year":2026,"published":"2026-09-17","venue":"Diagnostics (Basel, Switzerland)","cited_by":0,"doi":"10.3390/diagnostics16183009","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.3390/diagnostics16183009","archive_url":"https://space-kitty.com/papers/doi:10.3390/diagnostics16183009"},{"id":"doi:10.3390/life16091470","kind":"review","title":"The 2026 ACC/AHA Dyslipidemia Guideline: A Critical and Transatlantic Perspective on Personalized Lipid Management","authors":["Sabouret P","Mafrica D","Giamundo DM","Kalisz JP","Asher E","Atar D"],"author_count":7,"year":2026,"published":"2026-09-03","venue":"Life (Basel, Switzerland)","cited_by":0,"doi":"10.3390/life16091470","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.3390/life16091470","archive_url":"https://space-kitty.com/papers/doi:10.3390/life16091470"},{"id":"doi:10.1093/eurjpc/zwaf783","kind":"article","title":"Prediction of inclisiran efficacy in patients with established atherosclerotic cardiovascular disease: the SIRIUS in-silico modelling of cardiovascular outcomes","authors":["Angoulvant D","Peyronnet E","Cariou B","Amarenco P","Boccara F","Boissel JP"],"author_count":18,"year":2026,"published":"2026-09-01","venue":"European journal of preventive cardiology","cited_by":6,"doi":"10.1093/eurjpc/zwaf783","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1093/eurjpc/zwaf783","archive_url":"https://space-kitty.com/papers/doi:10.1093/eurjpc/zwaf783"},{"id":"doi:10.3390/reports9030284","kind":"article","title":"The Utilization of Inclisiran for the Optimization of Lipid Management in People Living with HIV: A Clinical Case Series and Comprehensive Review","authors":["Petrakis V","Panopoulou M","Grapsa A","Tsantes AG","Panagopoulos P"],"author_count":5,"year":2026,"published":"2026-08-25","venue":"Reports (MDPI)","cited_by":0,"doi":"10.3390/reports9030284","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.3390/reports9030284","archive_url":"https://space-kitty.com/papers/doi:10.3390/reports9030284"},{"id":"doi:10.31083/rcm48237","kind":"review","title":"A New Option for the Management of Dyslipidemias: Advances in Research on the Small Interfering RNA Drug Inclisiran","authors":["Wu X","Zhang J"],"author_count":2,"year":2026,"published":"2026-08-24","venue":"Reviews in cardiovascular medicine","cited_by":0,"doi":"10.31083/rcm48237","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.31083/rcm48237","archive_url":"https://space-kitty.com/papers/doi:10.31083/rcm48237"},{"id":"doi:10.1186/s12872-026-06429-w","kind":"article","title":"Inclisiran-induced LDL-cholesterol reduction with and without concomitant statin therapy: a real-world analysis","authors":["Seidel M","Seibert FS","Anft M","Stervbo U","Babel N","Westhoff TH"],"author_count":7,"year":2026,"published":"2026-08-15","venue":"BMC cardiovascular disorders","cited_by":0,"doi":"10.1186/s12872-026-06429-w","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1186/s12872-026-06429-w","archive_url":"https://space-kitty.com/papers/doi:10.1186/s12872-026-06429-w"},{"id":"doi:10.1016/j.ahj.2026.107546","kind":"article","title":"HPS-4/TIMI 65/ORION-4: A double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease: Trial design, recruitment, and baseline characteristics","authors":["Mafham MM","Zayed MG","Collins R","Sabatine MS","Armitage J","Brittain D"],"author_count":28,"year":2026,"published":"2026-08-07","venue":"American heart journal","cited_by":16,"doi":"10.1016/j.ahj.2026.107546","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1016/j.ahj.2026.107546","archive_url":"https://space-kitty.com/papers/doi:10.1016/j.ahj.2026.107546"}],"related_topics":[{"slug":"cancer-immunotherapy","name":"Cancer Immunotherapy","api_url":"https://space-kitty.com/api/v1/topics/cancer-immunotherapy"},{"slug":"mrna-cancer-vaccines","name":"mRNA Therapeutics & Cancer Vaccines","api_url":"https://space-kitty.com/api/v1/topics/mrna-cancer-vaccines"},{"slug":"gene-editing-therapies","name":"CRISPR & Gene-Editing Therapies","api_url":"https://space-kitty.com/api/v1/topics/gene-editing-therapies"},{"slug":"gene-cell-therapy","name":"Gene & Cell Therapy","api_url":"https://space-kitty.com/api/v1/topics/gene-cell-therapy"},{"slug":"glp1-metabolic","name":"GLP-1 & Incretin Therapies","api_url":"https://space-kitty.com/api/v1/topics/glp1-metabolic"},{"slug":"neurodegeneration","name":"Alzheimer's, Parkinson's & Neurodegeneration","api_url":"https://space-kitty.com/api/v1/topics/neurodegeneration"},{"slug":"aging-longevity","name":"Biology of Aging & Longevity","api_url":"https://space-kitty.com/api/v1/topics/aging-longevity"},{"slug":"infectious-disease-amr","name":"Infectious Disease, Vaccines & Antimicrobial Resistance","api_url":"https://space-kitty.com/api/v1/topics/infectious-disease-amr"},{"slug":"ai-medicine","name":"AI in Clinical Medicine","api_url":"https://space-kitty.com/api/v1/topics/ai-medicine"}],"premium":{"dossier":null,"research_pack":{"url":"https://space-kitty.com/api/v1/topics/cardiovascular-innovation/pack","price_usd":"0.20"}},"more":"https://space-kitty.com/api/v1/topics/cardiovascular-innovation/papers?sort=top&limit=100"}